Continuous Subcutaneous Insulin Infusion Market by Product Type (Conventional, Patch), Insulin Type (Rapid Acting Analog, Regular Insulin, Short Acting), Age Group, End User - Global Forecast 2025-2032
Description
The Continuous Subcutaneous Insulin Infusion Market was valued at USD 3.05 billion in 2024 and is projected to grow to USD 3.41 billion in 2025, with a CAGR of 12.51%, reaching USD 7.84 billion by 2032.
Framing the complex evolution of insulin delivery and digital therapeutics to illuminate where continuous subcutaneous insulin infusion is transforming chronic diabetes care
The executive summary opens by situating continuous subcutaneous insulin infusion (CSII) within a rapidly evolving therapeutic and technological environment where device innovation, integration with glucose sensing, and shifting payer dynamics are reshaping care pathways. CSII is increasingly recognized not only as a delivery mechanism but also as a platform for closed-loop therapy, data-enabled care, and digitally supported chronic disease management. As a result, stakeholders across clinical, regulatory, payer, and commercial domains are re-evaluating adoption criteria, operational workflows, and value propositions.
This opening section emphasizes the dual nature of CSII: it is a clinical intervention that improves glycemic regulation in eligible patients, and it is a digital health asset that can enable remote monitoring, algorithmic dosing, and longitudinal insights into adherence and outcomes. Clinicians and health systems are balancing device efficacy with usability, training burden, and interoperability with continuous glucose monitoring and electronic health records. Meanwhile, payers and procurement decision-makers seek evidence of economic and clinical value over conventional insulin delivery pathways. Throughout this report, the analysis remains rooted in the latest clinical guidance, device approvals, and technology interoperability trends, while addressing the barriers and enablers that influence real-world adoption and diffusion.
Analyzing the intersecting technological, regulatory, reimbursement, and evidence-generation forces that are redefining insulin pump therapy pathways and accelerating integrated care models
The CSII landscape is experiencing transformative shifts driven by four converging vectors: integration with continuous glucose monitoring and closed-loop algorithms, miniaturization and design improvements that expand usability, payer and reimbursement evolutions emphasizing outcomes, and the emergence of data ecosystems that enable population-level insights. Closed-loop systems that combine pumps with real-time glucose sensing and adaptive control algorithms are accelerating adoption by simplifying daily management and reducing glycemic variability. Concurrently, innovations in form factor, such as tubeless patch pumps and durable wearable systems, are lowering barriers related to visibility, physical activity, and lifestyle compatibility.
Regulatory and reimbursement environments are adapting to evidence frameworks focused on patient-centered outcomes, quality-of-life metrics, and total cost of care. This shift encourages manufacturers to invest in rigorous outcomes research and real-world evidence generation. At the same time, digital health infrastructure is maturing: interoperable data standards, cloud-based analytics, and clinician-facing dashboards are enabling scalable remote care programs. These shifts are not uniform across regions or care settings, so stakeholders must calibrate strategies to local clinical workflows, regulatory expectations, and payer models. Taken together, these dynamics are redefining devices from discrete products into integrated care solutions that blend hardware, software, services, and evidence-generation commitments.
Examining how tariff developments in 2025 altered procurement economics and supply chain resilience for continuous insulin delivery systems and industry stakeholders
The introduction of updated tariff regimes in the United States during 2025 has introduced complexities for suppliers and purchasers of CSII systems, affecting procurement strategies and global supply chain planning. Tariff adjustments have influenced landed costs, prompting manufacturers to reassess component sourcing, production footprints, and pricing strategies to maintain competitiveness and preserve access. Many manufacturers responded by accelerating localization of certain components, negotiating revised supplier contracts, and exploring tariff mitigation techniques such as tariff classification reviews and alternative logistics routes.
As a consequence, distributors and institutional buyers have re-evaluated contract terms, lead times, and inventory policies to mitigate exposure to cost volatility. Clinicians and health systems experienced intermittent procurement frictions, particularly for new product introductions that rely on global supply chains for electronics and precision components. In parallel, some manufacturers prioritized strategic investments in supply chain resiliency, including dual sourcing and regional assembly, to reduce tariff-driven operational risk. The broader lesson is that policy changes can rapidly alter commercial calculus; organizations that anticipate and model tariff impacts across procurement, pricing, and contracting processes are better positioned to sustain access and negotiate favorable terms during periods of regulatory change.
Unpacking the multi-dimensional segmentation across device type, insulin formulation, age cohort, and care setting to reveal nuanced adoption archetypes and product fit considerations
Segment-level dynamics reveal differentiated demand drivers and adoption pathways across product types, insulin formulations, age cohorts, and care settings. Based on product type, the landscape spans conventional pumps and patch pumps, with the conventional category itself differentiated between electronics-based pumps and mechanical pumps; this variation in form factor and functionality drives distinct clinical and commercial considerations related to programming flexibility, durability, and user training. Based on insulin type, therapy choices encompass rapid-acting analogs, regular insulin, and short-acting formulations, each presenting unique pharmacokinetic profiles that intersect with device algorithms and patient lifestyle needs.
Based on age group, adoption patterns vary across adults, geriatric populations, and pediatric patients, where factors such as cognitive load, caregiver involvement, and device tolerance inform device selection and support requirements. Based on end user, deployment and support models are shaped by ambulatory care, homecare environments, and hospital settings, which impose different expectations for device robustness, interoperability, and clinical oversight. When considered holistically, these segmentation dimensions produce multiple use-case archetypes: for example, a pediatric user on rapid-acting analog insulin managed in a homecare setting may prioritize patch pumps and caregiver-friendly interfaces, while an adult with complex comorbidities in a hospital or ambulatory specialty clinic may require an electronics-based pump capable of advanced programming and seamless CGM integration. Understanding these intersections enables manufacturers and providers to tailor product design, training, evidence generation, and reimbursement strategies for the most clinically impactful segments.
Evaluating how regional regulatory, reimbursement, and healthcare delivery differences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape adoption and strategic planning
Regional patterns in CSII adoption and ecosystem maturity exhibit distinct characteristics across the Americas, Europe, Middle East & Africa, and the Asia-Pacific region, shaping how companies prioritize go-to-market approaches and evidence generation. In the Americas, diverse payer models and pockets of advanced integrated care encourage rapid adoption of closed-loop systems and data-driven service offerings, although access remains heterogeneous across private and public payers. In Europe, Middle East & Africa, regulatory pathways and reimbursement criteria vary widely, prompting manufacturers to pursue region-specific clinical evidence and to build relations with national health technology assessment bodies to demonstrate patient-centered outcomes.
In the Asia-Pacific region, large and heterogeneous patient populations, rapid urbanization, and growing digital health infrastructure offer scale opportunities, but manufacturers must navigate variable regulatory processes, distribution channels, and local clinical practice patterns. These regional contrasts influence decisions about manufacturing localization, regulatory submission sequencing, and post-market evidence efforts. Moreover, cross-regional partnerships, technology transfer agreements, and regional centers of excellence for training and support can accelerate adoption while addressing local clinical and economic constraints. Stakeholders that align regulatory strategy, evidence generation, and commercial models with regional healthcare system priorities are better positioned to capture opportunities and support sustainable access to CSII therapy.
Profiling how established manufacturers and agile challengers compete through device innovation, software integration, evidence partnerships, and value-driven commercialization strategies
The competitive landscape is characterized by a mix of established medical device manufacturers, specialized diabetes technology companies, and newer entrants focused on wearable, software-driven solutions. Incumbent firms bring deep regulatory experience, established distribution networks, and relationships with clinicians and payers, while challenger companies are often differentiated by design-led approaches, patient-centric form factors, and rapid integration of algorithmic control and cloud-based data services. Strategic activity across the industry includes partnerships to integrate continuous glucose monitoring, acquisitions of software and algorithm capabilities, and alliances with clinical research networks to build real-world evidence.
Companies are investing in lifecycle management strategies that blend product iterations with services such as remote monitoring, clinician decision support, and patient education platforms. Many are also pursuing interoperability standards to simplify integration with electronic health records and third-party analytics. From a commercialization perspective, the most successful organizations align device innovation with payer-facing value narratives, robust post-market surveillance, and clinician training programs that reduce adoption friction. Ultimately, competitive differentiation increasingly rests on the ability to deliver demonstrable clinical and operational value through an integrated combination of device performance, digital services, and real-world evidence.
Actionable steps for manufacturers and health systems to accelerate clinical adoption, strengthen commercial resilience, and align device innovation with payer and patient priorities
Industry leaders can take targeted actions to accelerate adoption, reduce friction, and create defensible differentiation in CSII offerings. First, prioritize interoperable designs and open data standards so devices seamlessly exchange data with continuous glucose monitors, clinician dashboards, and health records, enabling integrated care pathways. Second, emphasize outcomes-driven evidence generation that includes patient-reported outcomes, quality-of-life measures, and real-world adherence data to support payer negotiations and clinical acceptance. Third, invest in localization of supply chain and regulatory strategy to reduce exposure to trade policy shifts and to strengthen time-to-market in priority regions.
Additionally, develop tiered commercial models that align product features and service levels with clinical need and payer willingness to reimburse, enabling broader access across diverse patient populations. Enhance patient and clinician onboarding through scalable training programs, telehealth-enabled support, and decision-support tools that reduce cognitive burden. Finally, pursue partnerships with digital health platforms and specialty care networks to expand post-market surveillance and to co-develop value-based contracting pilots. By taking these actions, organizations can improve clinical outcomes while building resilient commercial models that adapt to policy, payer, and technological changes.
Describing the rigorous mixed-methods research approach combining clinical interviews, regulatory review, and vendor assessment to produce actionable insights without predictive estimations
The research synthesized for this summary relies on a mixed-methods approach combining primary qualitative insights, secondary literature review, regulatory filings, and analysis of publicly available clinical guidance and device approvals. Primary qualitative inputs were gathered through structured interviews with clinicians, procurement specialists, payers, and device engineers to capture real-world adoption experiences, implementation barriers, and value perceptions. Secondary sources included peer-reviewed clinical studies, regulatory clearance summaries, and device specification documentation to validate technological trajectories and safety considerations.
Data synthesis emphasized triangulation across sources to ensure robustness: clinical perspectives were compared against device technical specifications and regulatory outcomes, while payer and procurement interviews were cross-referenced with publicly available reimbursement policies and procurement frameworks. The methodology also included scenario-based workshops to explore supply chain vulnerabilities and tariff impacts, and a structured vendor assessment to evaluate interoperability, evidence-generation capacity, and post-market support. Throughout, the analysis prioritized transparency about assumptions, and it focused on delivering actionable insights rather than predictive estimations.
Summarizing how integrated device, data, and evidence strategies will determine which CSII solutions deliver sustained clinical and operational value across diverse healthcare systems
This executive summary concludes that continuous subcutaneous insulin infusion is evolving from a device-centric therapy to an integrated care platform that pairs advanced hardware with sensing, analytics, and service components. The convergence of closed-loop algorithms, improved form factors, and maturing digital infrastructure is enhancing the therapy’s usability and clinical relevance across diverse patient groups. However, adoption trajectories are shaped by regional regulatory differences, payer expectations for outcomes, and the operational demands of training and support. Policymakers and purchasers must balance access with evidence requirements, while manufacturers must demonstrate real-world value through targeted studies and post-market data collection.
Looking ahead, the organizations that succeed will combine technical excellence with interoperability, evidence-generation, and flexible commercial models that reflect the diversity of clinical and regional needs. By aligning product roadmaps with clinician workflows, payer priorities, and patient preferences, stakeholders can expand appropriate access to CSII therapies and improve diabetes outcomes in a sustainable way. The insights presented here are intended to inform strategic choices and to catalyze action that bridges clinical efficacy, real-world effectiveness, and operational feasibility.
Please Note: PDF & Excel + Online Access - 1 Year
Framing the complex evolution of insulin delivery and digital therapeutics to illuminate where continuous subcutaneous insulin infusion is transforming chronic diabetes care
The executive summary opens by situating continuous subcutaneous insulin infusion (CSII) within a rapidly evolving therapeutic and technological environment where device innovation, integration with glucose sensing, and shifting payer dynamics are reshaping care pathways. CSII is increasingly recognized not only as a delivery mechanism but also as a platform for closed-loop therapy, data-enabled care, and digitally supported chronic disease management. As a result, stakeholders across clinical, regulatory, payer, and commercial domains are re-evaluating adoption criteria, operational workflows, and value propositions.
This opening section emphasizes the dual nature of CSII: it is a clinical intervention that improves glycemic regulation in eligible patients, and it is a digital health asset that can enable remote monitoring, algorithmic dosing, and longitudinal insights into adherence and outcomes. Clinicians and health systems are balancing device efficacy with usability, training burden, and interoperability with continuous glucose monitoring and electronic health records. Meanwhile, payers and procurement decision-makers seek evidence of economic and clinical value over conventional insulin delivery pathways. Throughout this report, the analysis remains rooted in the latest clinical guidance, device approvals, and technology interoperability trends, while addressing the barriers and enablers that influence real-world adoption and diffusion.
Analyzing the intersecting technological, regulatory, reimbursement, and evidence-generation forces that are redefining insulin pump therapy pathways and accelerating integrated care models
The CSII landscape is experiencing transformative shifts driven by four converging vectors: integration with continuous glucose monitoring and closed-loop algorithms, miniaturization and design improvements that expand usability, payer and reimbursement evolutions emphasizing outcomes, and the emergence of data ecosystems that enable population-level insights. Closed-loop systems that combine pumps with real-time glucose sensing and adaptive control algorithms are accelerating adoption by simplifying daily management and reducing glycemic variability. Concurrently, innovations in form factor, such as tubeless patch pumps and durable wearable systems, are lowering barriers related to visibility, physical activity, and lifestyle compatibility.
Regulatory and reimbursement environments are adapting to evidence frameworks focused on patient-centered outcomes, quality-of-life metrics, and total cost of care. This shift encourages manufacturers to invest in rigorous outcomes research and real-world evidence generation. At the same time, digital health infrastructure is maturing: interoperable data standards, cloud-based analytics, and clinician-facing dashboards are enabling scalable remote care programs. These shifts are not uniform across regions or care settings, so stakeholders must calibrate strategies to local clinical workflows, regulatory expectations, and payer models. Taken together, these dynamics are redefining devices from discrete products into integrated care solutions that blend hardware, software, services, and evidence-generation commitments.
Examining how tariff developments in 2025 altered procurement economics and supply chain resilience for continuous insulin delivery systems and industry stakeholders
The introduction of updated tariff regimes in the United States during 2025 has introduced complexities for suppliers and purchasers of CSII systems, affecting procurement strategies and global supply chain planning. Tariff adjustments have influenced landed costs, prompting manufacturers to reassess component sourcing, production footprints, and pricing strategies to maintain competitiveness and preserve access. Many manufacturers responded by accelerating localization of certain components, negotiating revised supplier contracts, and exploring tariff mitigation techniques such as tariff classification reviews and alternative logistics routes.
As a consequence, distributors and institutional buyers have re-evaluated contract terms, lead times, and inventory policies to mitigate exposure to cost volatility. Clinicians and health systems experienced intermittent procurement frictions, particularly for new product introductions that rely on global supply chains for electronics and precision components. In parallel, some manufacturers prioritized strategic investments in supply chain resiliency, including dual sourcing and regional assembly, to reduce tariff-driven operational risk. The broader lesson is that policy changes can rapidly alter commercial calculus; organizations that anticipate and model tariff impacts across procurement, pricing, and contracting processes are better positioned to sustain access and negotiate favorable terms during periods of regulatory change.
Unpacking the multi-dimensional segmentation across device type, insulin formulation, age cohort, and care setting to reveal nuanced adoption archetypes and product fit considerations
Segment-level dynamics reveal differentiated demand drivers and adoption pathways across product types, insulin formulations, age cohorts, and care settings. Based on product type, the landscape spans conventional pumps and patch pumps, with the conventional category itself differentiated between electronics-based pumps and mechanical pumps; this variation in form factor and functionality drives distinct clinical and commercial considerations related to programming flexibility, durability, and user training. Based on insulin type, therapy choices encompass rapid-acting analogs, regular insulin, and short-acting formulations, each presenting unique pharmacokinetic profiles that intersect with device algorithms and patient lifestyle needs.
Based on age group, adoption patterns vary across adults, geriatric populations, and pediatric patients, where factors such as cognitive load, caregiver involvement, and device tolerance inform device selection and support requirements. Based on end user, deployment and support models are shaped by ambulatory care, homecare environments, and hospital settings, which impose different expectations for device robustness, interoperability, and clinical oversight. When considered holistically, these segmentation dimensions produce multiple use-case archetypes: for example, a pediatric user on rapid-acting analog insulin managed in a homecare setting may prioritize patch pumps and caregiver-friendly interfaces, while an adult with complex comorbidities in a hospital or ambulatory specialty clinic may require an electronics-based pump capable of advanced programming and seamless CGM integration. Understanding these intersections enables manufacturers and providers to tailor product design, training, evidence generation, and reimbursement strategies for the most clinically impactful segments.
Evaluating how regional regulatory, reimbursement, and healthcare delivery differences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape adoption and strategic planning
Regional patterns in CSII adoption and ecosystem maturity exhibit distinct characteristics across the Americas, Europe, Middle East & Africa, and the Asia-Pacific region, shaping how companies prioritize go-to-market approaches and evidence generation. In the Americas, diverse payer models and pockets of advanced integrated care encourage rapid adoption of closed-loop systems and data-driven service offerings, although access remains heterogeneous across private and public payers. In Europe, Middle East & Africa, regulatory pathways and reimbursement criteria vary widely, prompting manufacturers to pursue region-specific clinical evidence and to build relations with national health technology assessment bodies to demonstrate patient-centered outcomes.
In the Asia-Pacific region, large and heterogeneous patient populations, rapid urbanization, and growing digital health infrastructure offer scale opportunities, but manufacturers must navigate variable regulatory processes, distribution channels, and local clinical practice patterns. These regional contrasts influence decisions about manufacturing localization, regulatory submission sequencing, and post-market evidence efforts. Moreover, cross-regional partnerships, technology transfer agreements, and regional centers of excellence for training and support can accelerate adoption while addressing local clinical and economic constraints. Stakeholders that align regulatory strategy, evidence generation, and commercial models with regional healthcare system priorities are better positioned to capture opportunities and support sustainable access to CSII therapy.
Profiling how established manufacturers and agile challengers compete through device innovation, software integration, evidence partnerships, and value-driven commercialization strategies
The competitive landscape is characterized by a mix of established medical device manufacturers, specialized diabetes technology companies, and newer entrants focused on wearable, software-driven solutions. Incumbent firms bring deep regulatory experience, established distribution networks, and relationships with clinicians and payers, while challenger companies are often differentiated by design-led approaches, patient-centric form factors, and rapid integration of algorithmic control and cloud-based data services. Strategic activity across the industry includes partnerships to integrate continuous glucose monitoring, acquisitions of software and algorithm capabilities, and alliances with clinical research networks to build real-world evidence.
Companies are investing in lifecycle management strategies that blend product iterations with services such as remote monitoring, clinician decision support, and patient education platforms. Many are also pursuing interoperability standards to simplify integration with electronic health records and third-party analytics. From a commercialization perspective, the most successful organizations align device innovation with payer-facing value narratives, robust post-market surveillance, and clinician training programs that reduce adoption friction. Ultimately, competitive differentiation increasingly rests on the ability to deliver demonstrable clinical and operational value through an integrated combination of device performance, digital services, and real-world evidence.
Actionable steps for manufacturers and health systems to accelerate clinical adoption, strengthen commercial resilience, and align device innovation with payer and patient priorities
Industry leaders can take targeted actions to accelerate adoption, reduce friction, and create defensible differentiation in CSII offerings. First, prioritize interoperable designs and open data standards so devices seamlessly exchange data with continuous glucose monitors, clinician dashboards, and health records, enabling integrated care pathways. Second, emphasize outcomes-driven evidence generation that includes patient-reported outcomes, quality-of-life measures, and real-world adherence data to support payer negotiations and clinical acceptance. Third, invest in localization of supply chain and regulatory strategy to reduce exposure to trade policy shifts and to strengthen time-to-market in priority regions.
Additionally, develop tiered commercial models that align product features and service levels with clinical need and payer willingness to reimburse, enabling broader access across diverse patient populations. Enhance patient and clinician onboarding through scalable training programs, telehealth-enabled support, and decision-support tools that reduce cognitive burden. Finally, pursue partnerships with digital health platforms and specialty care networks to expand post-market surveillance and to co-develop value-based contracting pilots. By taking these actions, organizations can improve clinical outcomes while building resilient commercial models that adapt to policy, payer, and technological changes.
Describing the rigorous mixed-methods research approach combining clinical interviews, regulatory review, and vendor assessment to produce actionable insights without predictive estimations
The research synthesized for this summary relies on a mixed-methods approach combining primary qualitative insights, secondary literature review, regulatory filings, and analysis of publicly available clinical guidance and device approvals. Primary qualitative inputs were gathered through structured interviews with clinicians, procurement specialists, payers, and device engineers to capture real-world adoption experiences, implementation barriers, and value perceptions. Secondary sources included peer-reviewed clinical studies, regulatory clearance summaries, and device specification documentation to validate technological trajectories and safety considerations.
Data synthesis emphasized triangulation across sources to ensure robustness: clinical perspectives were compared against device technical specifications and regulatory outcomes, while payer and procurement interviews were cross-referenced with publicly available reimbursement policies and procurement frameworks. The methodology also included scenario-based workshops to explore supply chain vulnerabilities and tariff impacts, and a structured vendor assessment to evaluate interoperability, evidence-generation capacity, and post-market support. Throughout, the analysis prioritized transparency about assumptions, and it focused on delivering actionable insights rather than predictive estimations.
Summarizing how integrated device, data, and evidence strategies will determine which CSII solutions deliver sustained clinical and operational value across diverse healthcare systems
This executive summary concludes that continuous subcutaneous insulin infusion is evolving from a device-centric therapy to an integrated care platform that pairs advanced hardware with sensing, analytics, and service components. The convergence of closed-loop algorithms, improved form factors, and maturing digital infrastructure is enhancing the therapy’s usability and clinical relevance across diverse patient groups. However, adoption trajectories are shaped by regional regulatory differences, payer expectations for outcomes, and the operational demands of training and support. Policymakers and purchasers must balance access with evidence requirements, while manufacturers must demonstrate real-world value through targeted studies and post-market data collection.
Looking ahead, the organizations that succeed will combine technical excellence with interoperability, evidence-generation, and flexible commercial models that reflect the diversity of clinical and regional needs. By aligning product roadmaps with clinician workflows, payer priorities, and patient preferences, stakeholders can expand appropriate access to CSII therapies and improve diabetes outcomes in a sustainable way. The insights presented here are intended to inform strategic choices and to catalyze action that bridges clinical efficacy, real-world effectiveness, and operational feasibility.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
187 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of continuous glucose monitoring data with advanced insulin pump algorithms enabling predictive insulin dosing adjustments in hybrid closed-loop systems
- 5.2. Development of tubeless patch pumps with smartphone connectivity and remote patient monitoring capabilities for enhanced adherence
- 5.3. Adoption of ultra-rapid-acting insulin formulations compatible with insulin pump therapy to improve postprandial glucose control
- 5.4. Implementation of artificial intelligence and machine learning models for personalized insulin delivery based on real-time lifestyle data
- 5.5. Expansion of reimbursement frameworks and digital health ecosystems to support telehealth initiation and management of insulin pump therapy
- 5.6. Collaboration between pharmaceutical companies and medical device manufacturers to co-develop interoperable closed-loop insulin delivery solutions
- 5.7. Surging demand for pediatric insulin pump systems featuring simplified user interfaces and customizable settings for young patients
- 5.8. Emergence of disposable patch pump systems with extended wear duration to reduce device maintenance burden for users
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Continuous Subcutaneous Insulin Infusion Market, by Product Type
- 8.1. Conventional
- 8.1.1. Electronics Based Pumps
- 8.1.2. Mechanical Pumps
- 8.2. Patch
- 9. Continuous Subcutaneous Insulin Infusion Market, by Insulin Type
- 9.1. Rapid Acting Analog
- 9.2. Regular Insulin
- 9.3. Short Acting
- 10. Continuous Subcutaneous Insulin Infusion Market, by Age Group
- 10.1. Adult
- 10.2. Geriatric
- 10.3. Pediatric
- 11. Continuous Subcutaneous Insulin Infusion Market, by End User
- 11.1. Ambulatory Care
- 11.2. Homecare
- 11.3. Hospitals
- 12. Continuous Subcutaneous Insulin Infusion Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Continuous Subcutaneous Insulin Infusion Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Continuous Subcutaneous Insulin Infusion Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. B. Braun SE
- 15.3.2. Baxter International, Inc.
- 15.3.3. Becton, Dickinson and Company
- 15.3.4. Bigfoot Biomedical, Inc.
- 15.3.5. BPL Medical Technologies Private Limited
- 15.3.6. CeQur SA
- 15.3.7. F. Hoffmann-La Roche Ltd.
- 15.3.8. Forbion
- 15.3.9. Fresenius SE & Co. KGaA
- 15.3.10. Insulet Corporation
- 15.3.11. MannKind Corporation
- 15.3.12. Medtronic PLC
- 15.3.13. MicroPort Scientific Corporation
- 15.3.14. Nipro Corporation
- 15.3.15. Pharmasense AG
- 15.3.16. Sanofi S.A.
- 15.3.17. Shinmyung Mediyes CO., LTD.
- 15.3.18. SOOIL Developments Co., Ltd.
- 15.3.19. Tandem Diabetes Care, Inc.
- 15.3.20. Terumo Group
- 15.3.21. Ypsomed AG
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
